Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to -$4.6 million.

  • Cytek Biosciences' Free Cash Flow fell 13730.55% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year decrease of 12049.51%. This contributed to the annual value of $21.9 million for FY2024, which is 335244.87% up from last year.
  • As of Q3 2025, Cytek Biosciences' Free Cash Flow stood at -$4.6 million, which was down 13730.55% from -$1.5 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Free Cash Flow registered a high of $12.2 million during Q3 2024, and its lowest value of -$10.8 million during Q2 2022.
  • Its 5-year average for Free Cash Flow is -$327578.9, with a median of -$337000.0 in 2022.
  • As far as peak fluctuations go, Cytek Biosciences' Free Cash Flow crashed by 575986.39% in 2022, and later soared by 247744.81% in 2023.
  • Quarter analysis of 5 years shows Cytek Biosciences' Free Cash Flow stood at $4.2 million in 2021, then plummeted by 108.12% to -$337000.0 in 2022, then soared by 2477.45% to $8.0 million in 2023, then plummeted by 86.23% to $1.1 million in 2024, then tumbled by 512.96% to -$4.6 million in 2025.
  • Its Free Cash Flow stands at -$4.6 million for Q3 2025, versus -$1.5 million for Q2 2025 and -$974000.0 for Q1 2025.